• AI driven workflows shorten development timelines by 10-20%
  • Medical affairs teams generate faster insights and stronger HCP engagement
  • AI powered patient support improve adherence by 5-15% percent
  • Commercial teams gaining clearer performance attribution across channels

    The State of AI
    in Biopharma

    Biopharma organizations are under pressure to move faster while proving value across development, medical affairs, and commercialization. In 2026, AI is becoming the connective layer across the lifecycle.

    This report explores how AI is accelerating timelines, scaling medical insight, and improving patient access and engagement with measurable results.